References
- Haubeck H-D, Kolsch E. Isolation and characterization of in vitro and in vivo functions of a tumor-specific T suppressor cell clone from a BALB/c mouse bearing the syngeneic ADJ-PC-5 plasmacytoma. J Immunol 1985; 135: 4297–4301
- North R J. Down-regulation of the antitumor immune response. Adv Cancer Res 1985; 45: 1–43
- Greene M I. The genetic and cellular basis of regulation of the immune response to tumor antigens. Contemp Top Immunobiol 1980; 11: 81–116
- Nagarkatti M, Kaplan A M. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor. J Immunol 1985; 135: 1510–1517
- Hengst J CD, Mokyr M B, Dray S. Importance of timing of cyclophosphamide therapy of MOPC-315 tumor bearing mice. Cancer Res 1980; 40: 2135–2141
- Shanahan T C, Ceglowski W S, Havas H F. Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment. Cancer Res 1985; 45: 6463–6470
- Hengst J CD, Mokyr M B, Dray S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 1981; 41: 2163–2167
- Mokyr M B, Hengst J CD, Dray S. The role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Cancer Res 1982; 42: 974–979
- Mokyr M B, Dray S. Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Invest 1987; 5: 31–38
- Miura T, Ghanta V K, Hiramoto R N. Host response to myeloma: I. Induction of cytotoxic and suppressor T cells by in vivo immunization with MOPC 104E plasmacytoma. Cancer Inves 1987; 6: 1
- Berd D, Maguire H C, Mastrangelo M J. Induction of cell-mediated immunity to autologous melanoma cell and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 2572–2577